27804215|t|Simultaneously Targeting Myofibroblast Contractility and Extracellular Matrix Cross-Linking as a Therapeutic Concept in Airway Fibrosis
27804215|a|Fibrosis after solid organ transplantation is considered an irreversible process and remains the major cause of graft dysfunction and death with limited therapies. This remodeling is characterized by aberrant accumulation of contractile myofibroblasts that deposit excessive extracellular matrix (ECM) and increase tissue stiffness. Studies demonstrate, however, that a stiff ECM itself promotes fibroblast -to- myofibroblast differentiation, stimulating further ECM production. This creates a positive feedback loop that perpetuates fibrosis. We hypothesized that simultaneously targeting myofibroblast contractility with relaxin and ECM stiffness with lysyl oxidase inhibitors could break the feedback loop, reversing established fibrosis. To test this, we used the orthotopic tracheal transplantation (OTT) mouse model, which develops robust fibrotic airway remodeling. Mice with established fibrosis were treated with saline, mono-, or combination therapies. Although monotherapies had no effect, combining these agents decreased collagen deposition and promoted re-epithelialization of remodeled airways. Relaxin inhibited myofibroblast differentiation and contraction in a matrix - stiffness - dependent manner through prostaglandin E2 (PGE2). Furthermore, the effect of combination therapy was lost in PGE2 receptor knockout and PGE2 - inhibited OTT mice. This study revealed the important synergistic roles of cellular contractility and tissue stiffness in the maintenance of fibrotic tissue and suggests a new therapeutic principle for fibrosis.
27804215	25	52	Myofibroblast Contractility	T038	UMLS:C4235370
27804215	57	77	Extracellular Matrix	T017	UMLS:C0015350
27804215	120	126	Airway	T017	UMLS:C0458827
27804215	127	135	Fibrosis	T038	UMLS:C0016059
27804215	136	144	Fibrosis	T038	UMLS:C0016059
27804215	151	178	solid organ transplantation	T058	UMLS:C0029216
27804215	248	265	graft dysfunction	T038	UMLS:C1167870
27804215	270	275	death	T038	UMLS:C0011065
27804215	289	298	therapies	T058	UMLS:C0087111
27804215	345	357	accumulation	T033	UMLS:C4055506
27804215	361	387	contractile myofibroblasts	T017	UMLS:C0225360
27804215	411	431	extracellular matrix	T017	UMLS:C0015350
27804215	433	436	ECM	T017	UMLS:C0015350
27804215	469	476	Studies	T062	UMLS:C2603343
27804215	506	511	stiff	T033	UMLS:C0427008
27804215	512	515	ECM	T017	UMLS:C0015350
27804215	532	542	fibroblast	T017	UMLS:C0016030
27804215	548	561	myofibroblast	T017	UMLS:C0225360
27804215	562	577	differentiation	T038	UMLS:C0007589
27804215	599	602	ECM	T017	UMLS:C0015350
27804215	670	678	fibrosis	T038	UMLS:C0016059
27804215	726	753	myofibroblast contractility	T038	UMLS:C4235370
27804215	759	766	relaxin	T103	UMLS:C0035031
27804215	771	774	ECM	T017	UMLS:C0015350
27804215	775	784	stiffness	T033	UMLS:C0427008
27804215	790	803	lysyl oxidase	T103	UMLS:C0024375
27804215	804	814	inhibitors	T103	UMLS:C0014432
27804215	831	844	feedback loop	T038	UMLS:C0678663
27804215	868	876	fibrosis	T038	UMLS:C0016059
27804215	904	939	orthotopic tracheal transplantation	T058	UMLS:C0040732
27804215	941	944	OTT	T058	UMLS:C0040732
27804215	946	957	mouse model	T038	UMLS:C2986594
27804215	990	996	airway	T017	UMLS:C0458827
27804215	1009	1013	Mice	T204	UMLS:C0025929
27804215	1031	1039	fibrosis	T038	UMLS:C0016059
27804215	1066	1071	mono-	T058	UMLS:C0520016
27804215	1076	1097	combination therapies	T058	UMLS:C0013218
27804215	1108	1121	monotherapies	T058	UMLS:C0520016
27804215	1137	1159	combining these agents	T103	UMLS:C0013162
27804215	1170	1178	collagen	T103	UMLS:C0009325
27804215	1203	1223	re-epithelialization	T038	UMLS:C0334221
27804215	1227	1244	remodeled airways	T033	UMLS:C2717792
27804215	1246	1253	Relaxin	T103	UMLS:C0035031
27804215	1264	1277	myofibroblast	T017	UMLS:C0225360
27804215	1278	1293	differentiation	T038	UMLS:C0007589
27804215	1298	1309	contraction	T038	UMLS:C1140999
27804215	1315	1321	matrix	T017	UMLS:C0015350
27804215	1324	1333	stiffness	T033	UMLS:C0427008
27804215	1361	1377	prostaglandin E2	T103	UMLS:C3813211
27804215	1379	1383	PGE2	T103	UMLS:C3813211
27804215	1413	1432	combination therapy	T058	UMLS:C0013218
27804215	1445	1458	PGE2 receptor	T103	UMLS:C0034835
27804215	1459	1467	knockout	T204	UMLS:C0206745
27804215	1472	1476	PGE2	T103	UMLS:C3813211
27804215	1489	1492	OTT	T058	UMLS:C0040732
27804215	1493	1497	mice	T204	UMLS:C0025929
27804215	1504	1509	study	T062	UMLS:C2603343
27804215	1554	1576	cellular contractility	T038	UMLS:C1140999
27804215	1629	1635	tissue	T017	UMLS:C0040300
27804215	1681	1689	fibrosis	T038	UMLS:C0016059